Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Вакцинация от вируса папилломы человека: доказательная база эффективности и безопасности
Вакцинация от вируса папилломы человека: доказательная база эффективности и безопасности
Доброхотова Ю.Э., Боровкова Е.И. Вакцинация от вируса папилломы человека: доказательная база эффективности и безопасности. Гинекология. 2021; 23 (2): 125–130. DOI: 10.26442/20795696.2021.2.200742
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Представлен обзор литературы, посвященный профилактике развития рака шейки матки путем проведения вакцинации от вируса папилломы человека (ВПЧ). В настоящее время внедрены 3 вакцины: 4-валентная вакцина от 6, 11, 16 и 18-го типов ВПЧ, 9-валентная вакцина от 6, 11, 16, 18, 31, 33, 45, 52, 58-го типов и бивалентная вакцина от ВПЧ 16 и 18-го типов. Вакцинация обеспечивает защиту для женщин и мужчин от инфицирования и развития в последующем ВПЧ-ассоциированных заболеваний. После иммунизации сероконверсия развивается у 93–100% женщин и у 99–100% мужчин и эффективна в отношении предотвращения инцидентной и персистирующей ВПЧ-инфекции и развития цервикальной интраэпителиальной неоплазии. Иммунизация против ВПЧ неэффективна для устранения уже имеющейся инфекции ВПЧ, генитальных бородавок или аногенитальной интраэпителиальной неоплазии. Статус вакцинации против ВПЧ не влияет на рекомендации по скринингу рака шейки матки.
Ключевые слова: вирус папилломы человека, вакцинация, рак шейки матки
Keywords: human papillomavirus, vaccination, cervical cancer
Ключевые слова: вирус папилломы человека, вакцинация, рак шейки матки
________________________________________________
Keywords: human papillomavirus, vaccination, cervical cancer
Полный текст
Список литературы
1. Trimble CL, Morrow MP, Kraynyak KA, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015; 386: 2078.
2. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003; 9: 37.
3. Drolet M, Bénard É, Pérez N, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019; 394: 497.
4. Freedman M, Kroger A, Hunter P, et al. Recommended Adult Immunization Schedule, United States, 2020. Ann Intern Med. 2020; 172: 337.
5. Robinson CL, Bernstein H, Poehling K, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger – United States, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69: 130.
6. Meites E, Szilagyi PG, Chesson HW, et al. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019; 68: 698.
7. Laprise JF, Chesson HW, Markowitz LE, et al. Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States. Ann Intern Med. 2020; 172: 22.
8. Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016; 16: 1154.
9. Immunization Expert Work Group, Committee on Adolescent Health Care. Committee Opinion No. 704: Human Papillomavirus Vaccination. Obstet Gynecol. 2017; 129: e173.
10. Huang LM, Puthanakit T, Cheng-Hsun C, et al. Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial. J Infect Dis. 2017; 215: 1711.
11. International Papillomavirus Society (IPVS). Available at: http://ipvsoc.org/. Accessed: 05.07.2017.
12. Joura EA, Kyrgiou M, Bosch FX, et al. Human papillomavirus vaccination: The ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy. Eur J Cancer. 2019; 116: 21.
13. Arrossi S, Temin S, Garland S, et al. Primary prevention of cervical cancer: American Society of Clinical Oncology resource-stratified guideline. March 17, 2017. Available at: http://www.asco.org/practice-guidelines/quality-guidelines/guidelines/resource-stratified?et_cid=390.... Accessed: 17.03.2017.
14. Human papillomavirus vaccines: WHO position paper, May 2017. Available at: http://apps.who.int/iris/bitstream/10665/255353/1/WER9219.pdf?ua=1.
15. Sankaranarayanan R, Prabhu PR, Pawlita M, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol. 2016; 17: 67.
16. Puthanakit T, Huang LM, Chiu CH, et al. Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15–25 Years. J Infect Dis. 2016; 214: 525.
17. Iversen OE, Miranda MJ, Ulied A, et al. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women. JAMA. 2016; 316: 2411.
18. Ogilvie G, Sauvageau C, Dionne M, et al. Immunogenicity of 2 vs 3 Doses of the Quadrivalent Human Papillomavirus Vaccine in Girls Aged 9 to 13 Years After 60 Months. JAMA. 2017; 317: 1687.
19. Rodriguez AM, Zeybek B, Vaughn M, et al. Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study. Cancer. 2020; 126: 1656.
20. Verdoodt F, Dehlendorff C, Kjaer SK. Dose-related Effectiveness of Quadrivalent Human Papillomavirus Vaccine Against Cervical Intraepithelial Neoplasia: A Danish Nationwide Cohort Study. Clin Infect Dis. 2020; 70: 608.
21. McClymont E, Lee M, Raboud J, et al. The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living With Human Immunodeficiency Virus. Clin Infect Dis. 2019; 68: 788.
22. Wilkin TJ, Chen H, Cespedes MS, et al. A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis. 2018; 67: 1339.
23. Moscicki AB, Karalius B, Tassiopoulos K, et al. Human Papillomavirus Antibody Levels and Quadrivalent Vaccine Clinical Effectiveness in Perinatally Human Immunodeficiency Virus-infected and Exposed, Uninfected Youth. Clin Infect Dis. 2019; 69: 1183.
24. Brophy J, Bitnun A, Alimenti A, et al. Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIV. Pediatr Infect Dis J. 2018; 37: 595.
25. Levin MJ, Huang S, Moscicki AB, et al. Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine. Vaccine. 2017; 35: 1712.
26. Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018; 5: CD009069.
27. Novakovic D, Cheng ATL, Zurynski Y, et al. A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program. J Infect Dis. 2018; 217: 208.
28. Rosenberg T, Philipsen BB, Mehlum CS, et al. Therapeutic Use of the Human Papillomavirus Vaccine on Recurrent Respiratory Papillomatosis: A Systematic Review and Meta-Analysis. J Infect Dis. 2019; 219: 1016.
29. Toh ZQ, Russell FM, Reyburn R, et al. Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study. Clin Infect Dis. 2017; 64: 852.
30. Vaccine uptake guidance and the latest coverage data. Public Health England. Available at: https://www.gov.uk/government/collections/vaccine-uptake. Accessed: 20.07.2015.
31. Saslow D, Andrews KS, Manassaram-Baptiste D, et al. Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement. CA Cancer J Clin. 2016; 66: 375.
2. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003; 9: 37.
3. Drolet M, Bénard É, Pérez N, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019; 394: 497.
4. Freedman M, Kroger A, Hunter P, et al. Recommended Adult Immunization Schedule, United States, 2020. Ann Intern Med. 2020; 172: 337.
5. Robinson CL, Bernstein H, Poehling K, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger – United States, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69: 130.
6. Meites E, Szilagyi PG, Chesson HW, et al. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019; 68: 698.
7. Laprise JF, Chesson HW, Markowitz LE, et al. Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States. Ann Intern Med. 2020; 172: 22.
8. Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016; 16: 1154.
9. Immunization Expert Work Group, Committee on Adolescent Health Care. Committee Opinion No. 704: Human Papillomavirus Vaccination. Obstet Gynecol. 2017; 129: e173.
10. Huang LM, Puthanakit T, Cheng-Hsun C, et al. Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial. J Infect Dis. 2017; 215: 1711.
11. International Papillomavirus Society (IPVS). Available at: http://ipvsoc.org/. Accessed: 05.07.2017.
12. Joura EA, Kyrgiou M, Bosch FX, et al. Human papillomavirus vaccination: The ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy. Eur J Cancer. 2019; 116: 21.
13. Arrossi S, Temin S, Garland S, et al. Primary prevention of cervical cancer: American Society of Clinical Oncology resource-stratified guideline. March 17, 2017. Available at: http://www.asco.org/practice-guidelines/quality-guidelines/guidelines/resource-stratified?et_cid=390.... Accessed: 17.03.2017.
14. Human papillomavirus vaccines: WHO position paper, May 2017. Available at: http://apps.who.int/iris/bitstream/10665/255353/1/WER9219.pdf?ua=1.
15. Sankaranarayanan R, Prabhu PR, Pawlita M, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol. 2016; 17: 67.
16. Puthanakit T, Huang LM, Chiu CH, et al. Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15–25 Years. J Infect Dis. 2016; 214: 525.
17. Iversen OE, Miranda MJ, Ulied A, et al. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women. JAMA. 2016; 316: 2411.
18. Ogilvie G, Sauvageau C, Dionne M, et al. Immunogenicity of 2 vs 3 Doses of the Quadrivalent Human Papillomavirus Vaccine in Girls Aged 9 to 13 Years After 60 Months. JAMA. 2017; 317: 1687.
19. Rodriguez AM, Zeybek B, Vaughn M, et al. Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study. Cancer. 2020; 126: 1656.
20. Verdoodt F, Dehlendorff C, Kjaer SK. Dose-related Effectiveness of Quadrivalent Human Papillomavirus Vaccine Against Cervical Intraepithelial Neoplasia: A Danish Nationwide Cohort Study. Clin Infect Dis. 2020; 70: 608.
21. McClymont E, Lee M, Raboud J, et al. The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living With Human Immunodeficiency Virus. Clin Infect Dis. 2019; 68: 788.
22. Wilkin TJ, Chen H, Cespedes MS, et al. A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis. 2018; 67: 1339.
23. Moscicki AB, Karalius B, Tassiopoulos K, et al. Human Papillomavirus Antibody Levels and Quadrivalent Vaccine Clinical Effectiveness in Perinatally Human Immunodeficiency Virus-infected and Exposed, Uninfected Youth. Clin Infect Dis. 2019; 69: 1183.
24. Brophy J, Bitnun A, Alimenti A, et al. Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIV. Pediatr Infect Dis J. 2018; 37: 595.
25. Levin MJ, Huang S, Moscicki AB, et al. Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine. Vaccine. 2017; 35: 1712.
26. Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018; 5: CD009069.
27. Novakovic D, Cheng ATL, Zurynski Y, et al. A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program. J Infect Dis. 2018; 217: 208.
28. Rosenberg T, Philipsen BB, Mehlum CS, et al. Therapeutic Use of the Human Papillomavirus Vaccine on Recurrent Respiratory Papillomatosis: A Systematic Review and Meta-Analysis. J Infect Dis. 2019; 219: 1016.
29. Toh ZQ, Russell FM, Reyburn R, et al. Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study. Clin Infect Dis. 2017; 64: 852.
30. Vaccine uptake guidance and the latest coverage data. Public Health England. Available at: https://www.gov.uk/government/collections/vaccine-uptake. Accessed: 20.07.2015.
31. Saslow D, Andrews KS, Manassaram-Baptiste D, et al. Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement. CA Cancer J Clin. 2016; 66: 375.
2. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003; 9: 37.
3. Drolet M, Bénard É, Pérez N, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019; 394: 497.
4. Freedman M, Kroger A, Hunter P, et al. Recommended Adult Immunization Schedule, United States, 2020. Ann Intern Med. 2020; 172: 337.
5. Robinson CL, Bernstein H, Poehling K, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger – United States, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69: 130.
6. Meites E, Szilagyi PG, Chesson HW, et al. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019; 68: 698.
7. Laprise JF, Chesson HW, Markowitz LE, et al. Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States. Ann Intern Med. 2020; 172: 22.
8. Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016; 16: 1154.
9. Immunization Expert Work Group, Committee on Adolescent Health Care. Committee Opinion No. 704: Human Papillomavirus Vaccination. Obstet Gynecol. 2017; 129: e173.
10. Huang LM, Puthanakit T, Cheng-Hsun C, et al. Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial. J Infect Dis. 2017; 215: 1711.
11. International Papillomavirus Society (IPVS). Available at: http://ipvsoc.org/. Accessed: 05.07.2017.
12. Joura EA, Kyrgiou M, Bosch FX, et al. Human papillomavirus vaccination: The ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy. Eur J Cancer. 2019; 116: 21.
13. Arrossi S, Temin S, Garland S, et al. Primary prevention of cervical cancer: American Society of Clinical Oncology resource-stratified guideline. March 17, 2017. Available at: http://www.asco.org/practice-guidelines/quality-guidelines/guidelines/resource-stratified?et_cid=390.... Accessed: 17.03.2017.
14. Human papillomavirus vaccines: WHO position paper, May 2017. Available at: http://apps.who.int/iris/bitstream/10665/255353/1/WER9219.pdf?ua=1.
15. Sankaranarayanan R, Prabhu PR, Pawlita M, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol. 2016; 17: 67.
16. Puthanakit T, Huang LM, Chiu CH, et al. Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15–25 Years. J Infect Dis. 2016; 214: 525.
17. Iversen OE, Miranda MJ, Ulied A, et al. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women. JAMA. 2016; 316: 2411.
18. Ogilvie G, Sauvageau C, Dionne M, et al. Immunogenicity of 2 vs 3 Doses of the Quadrivalent Human Papillomavirus Vaccine in Girls Aged 9 to 13 Years After 60 Months. JAMA. 2017; 317: 1687.
19. Rodriguez AM, Zeybek B, Vaughn M, et al. Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study. Cancer. 2020; 126: 1656.
20. Verdoodt F, Dehlendorff C, Kjaer SK. Dose-related Effectiveness of Quadrivalent Human Papillomavirus Vaccine Against Cervical Intraepithelial Neoplasia: A Danish Nationwide Cohort Study. Clin Infect Dis. 2020; 70: 608.
21. McClymont E, Lee M, Raboud J, et al. The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living With Human Immunodeficiency Virus. Clin Infect Dis. 2019; 68: 788.
22. Wilkin TJ, Chen H, Cespedes MS, et al. A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis. 2018; 67: 1339.
23. Moscicki AB, Karalius B, Tassiopoulos K, et al. Human Papillomavirus Antibody Levels and Quadrivalent Vaccine Clinical Effectiveness in Perinatally Human Immunodeficiency Virus-infected and Exposed, Uninfected Youth. Clin Infect Dis. 2019; 69: 1183.
24. Brophy J, Bitnun A, Alimenti A, et al. Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIV. Pediatr Infect Dis J. 2018; 37: 595.
25. Levin MJ, Huang S, Moscicki AB, et al. Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine. Vaccine. 2017; 35: 1712.
26. Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018; 5: CD009069.
27. Novakovic D, Cheng ATL, Zurynski Y, et al. A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program. J Infect Dis. 2018; 217: 208.
28. Rosenberg T, Philipsen BB, Mehlum CS, et al. Therapeutic Use of the Human Papillomavirus Vaccine on Recurrent Respiratory Papillomatosis: A Systematic Review and Meta-Analysis. J Infect Dis. 2019; 219: 1016.
29. Toh ZQ, Russell FM, Reyburn R, et al. Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study. Clin Infect Dis. 2017; 64: 852.
30. Vaccine uptake guidance and the latest coverage data. Public Health England. Available at: https://www.gov.uk/government/collections/vaccine-uptake. Accessed: 20.07.2015.
31. Saslow D, Andrews KS, Manassaram-Baptiste D, et al. Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement. CA Cancer J Clin. 2016; 66: 375.
________________________________________________
2. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003; 9: 37.
3. Drolet M, Bénard É, Pérez N, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019; 394: 497.
4. Freedman M, Kroger A, Hunter P, et al. Recommended Adult Immunization Schedule, United States, 2020. Ann Intern Med. 2020; 172: 337.
5. Robinson CL, Bernstein H, Poehling K, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger – United States, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69: 130.
6. Meites E, Szilagyi PG, Chesson HW, et al. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019; 68: 698.
7. Laprise JF, Chesson HW, Markowitz LE, et al. Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States. Ann Intern Med. 2020; 172: 22.
8. Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016; 16: 1154.
9. Immunization Expert Work Group, Committee on Adolescent Health Care. Committee Opinion No. 704: Human Papillomavirus Vaccination. Obstet Gynecol. 2017; 129: e173.
10. Huang LM, Puthanakit T, Cheng-Hsun C, et al. Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial. J Infect Dis. 2017; 215: 1711.
11. International Papillomavirus Society (IPVS). Available at: http://ipvsoc.org/. Accessed: 05.07.2017.
12. Joura EA, Kyrgiou M, Bosch FX, et al. Human papillomavirus vaccination: The ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy. Eur J Cancer. 2019; 116: 21.
13. Arrossi S, Temin S, Garland S, et al. Primary prevention of cervical cancer: American Society of Clinical Oncology resource-stratified guideline. March 17, 2017. Available at: http://www.asco.org/practice-guidelines/quality-guidelines/guidelines/resource-stratified?et_cid=390.... Accessed: 17.03.2017.
14. Human papillomavirus vaccines: WHO position paper, May 2017. Available at: http://apps.who.int/iris/bitstream/10665/255353/1/WER9219.pdf?ua=1.
15. Sankaranarayanan R, Prabhu PR, Pawlita M, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol. 2016; 17: 67.
16. Puthanakit T, Huang LM, Chiu CH, et al. Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15–25 Years. J Infect Dis. 2016; 214: 525.
17. Iversen OE, Miranda MJ, Ulied A, et al. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women. JAMA. 2016; 316: 2411.
18. Ogilvie G, Sauvageau C, Dionne M, et al. Immunogenicity of 2 vs 3 Doses of the Quadrivalent Human Papillomavirus Vaccine in Girls Aged 9 to 13 Years After 60 Months. JAMA. 2017; 317: 1687.
19. Rodriguez AM, Zeybek B, Vaughn M, et al. Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study. Cancer. 2020; 126: 1656.
20. Verdoodt F, Dehlendorff C, Kjaer SK. Dose-related Effectiveness of Quadrivalent Human Papillomavirus Vaccine Against Cervical Intraepithelial Neoplasia: A Danish Nationwide Cohort Study. Clin Infect Dis. 2020; 70: 608.
21. McClymont E, Lee M, Raboud J, et al. The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living With Human Immunodeficiency Virus. Clin Infect Dis. 2019; 68: 788.
22. Wilkin TJ, Chen H, Cespedes MS, et al. A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis. 2018; 67: 1339.
23. Moscicki AB, Karalius B, Tassiopoulos K, et al. Human Papillomavirus Antibody Levels and Quadrivalent Vaccine Clinical Effectiveness in Perinatally Human Immunodeficiency Virus-infected and Exposed, Uninfected Youth. Clin Infect Dis. 2019; 69: 1183.
24. Brophy J, Bitnun A, Alimenti A, et al. Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIV. Pediatr Infect Dis J. 2018; 37: 595.
25. Levin MJ, Huang S, Moscicki AB, et al. Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine. Vaccine. 2017; 35: 1712.
26. Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018; 5: CD009069.
27. Novakovic D, Cheng ATL, Zurynski Y, et al. A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program. J Infect Dis. 2018; 217: 208.
28. Rosenberg T, Philipsen BB, Mehlum CS, et al. Therapeutic Use of the Human Papillomavirus Vaccine on Recurrent Respiratory Papillomatosis: A Systematic Review and Meta-Analysis. J Infect Dis. 2019; 219: 1016.
29. Toh ZQ, Russell FM, Reyburn R, et al. Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study. Clin Infect Dis. 2017; 64: 852.
30. Vaccine uptake guidance and the latest coverage data. Public Health England. Available at: https://www.gov.uk/government/collections/vaccine-uptake. Accessed: 20.07.2015.
31. Saslow D, Andrews KS, Manassaram-Baptiste D, et al. Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement. CA Cancer J Clin. 2016; 66: 375.
Авторы
Ю.Э. Доброхотова*, Е.И. Боровкова
ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия
*pr.dobrohotova@mail.ru
Pirogov Russian National Research Medical University, Moscow, Russia
*pr.dobrohotova@mail.ru
ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия
*pr.dobrohotova@mail.ru
________________________________________________
Pirogov Russian National Research Medical University, Moscow, Russia
*pr.dobrohotova@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.